168 related articles for article (PubMed ID: 16489021)
21. C-myc overexpression and p53 loss cooperate to promote genomic instability.
Yin XY; Grove L; Datta NS; Long MW; Prochownik EV
Oncogene; 1999 Feb; 18(5):1177-84. PubMed ID: 10022123
[TBL] [Abstract][Full Text] [Related]
22. Inhibitory effect of c-Myc on p53-induced apoptosis in leukemia cells. Microarray analysis reveals defective induction of p53 target genes and upregulation of chaperone genes.
Ceballos E; Muñoz-Alonso MJ; Berwanger B; Acosta JC; Hernández R; Krause M; Hartmann O; Eilers M; León J
Oncogene; 2005 Jun; 24(28):4559-71. PubMed ID: 15856024
[TBL] [Abstract][Full Text] [Related]
23. Evidence that c-myc mediated apoptosis does not require wild-type p53 during lymphomagenesis.
Hsu B; Marin MC; el-Naggar AK; Stephens LC; Brisbay S; McDonnell TJ
Oncogene; 1995 Jul; 11(1):175-9. PubMed ID: 7624125
[TBL] [Abstract][Full Text] [Related]
24. Interactions between MYC and transforming growth factor alpha alter the growth and tumorigenicity of liver progenitor cells.
Cheung RS; Brooling JT; Johnson MM; Riehle KJ; Campbell JS; Fausto N
Carcinogenesis; 2007 Dec; 28(12):2624-31. PubMed ID: 17698969
[TBL] [Abstract][Full Text] [Related]
25. Proviral insertion indicates a dominant oncogenic role for Runx1/AML-1 in T-cell lymphoma.
Wotton S; Stewart M; Blyth K; Vaillant F; Kilbey A; Neil JC; Cameron ER
Cancer Res; 2002 Dec; 62(24):7181-5. PubMed ID: 12499254
[TBL] [Abstract][Full Text] [Related]
26. Modeling the therapeutic efficacy of p53 restoration in tumors.
Martins CP; Brown-Swigart L; Evan GI
Cell; 2006 Dec; 127(7):1323-34. PubMed ID: 17182091
[TBL] [Abstract][Full Text] [Related]
27. Nucleophosmin is required for DNA integrity and p19Arf protein stability.
Colombo E; Bonetti P; Lazzerini Denchi E; Martinelli P; Zamponi R; Marine JC; Helin K; Falini B; Pelicci PG
Mol Cell Biol; 2005 Oct; 25(20):8874-86. PubMed ID: 16199867
[TBL] [Abstract][Full Text] [Related]
28. Synergistic effect of cyclin D1 and c-Myc leads to more aggressive and invasive mammary tumors in severe combined immunodeficient mice.
Wang Y; Thakur A; Sun Y; Wu J; Biliran H; Bollig A; Liao DJ
Cancer Res; 2007 Apr; 67(8):3698-707. PubMed ID: 17440082
[TBL] [Abstract][Full Text] [Related]
29. Mnt-deficient mammary glands exhibit impaired involution and tumors with characteristics of myc overexpression.
Toyo-oka K; Bowen TJ; Hirotsune S; Li Z; Jain S; Ota S; Escoubet-Lozach L; Garcia-Bassets I; Lozach J; Rosenfeld MG; Glass CK; Eisenman R; Ren B; Hurlin P; Wynshaw-Boris A
Cancer Res; 2006 Jun; 66(11):5565-73. PubMed ID: 16740691
[TBL] [Abstract][Full Text] [Related]
30. Oncogenic transformation of human ovarian surface epithelial cells with defined cellular oncogenes.
Sasaki R; Narisawa-Saito M; Yugawa T; Fujita M; Tashiro H; Katabuchi H; Kiyono T
Carcinogenesis; 2009 Mar; 30(3):423-31. PubMed ID: 19126650
[TBL] [Abstract][Full Text] [Related]
31. Pim1 and Myc reversibly transform murine precursor B lymphocytes but not mature B lymphocytes.
Bouquet C; Melchers F
Eur J Immunol; 2012 Feb; 42(2):522-32. PubMed ID: 22101984
[TBL] [Abstract][Full Text] [Related]
32. The helix-loop-helix protein Id2 is expressed differentially and induced by myc in T-cell lymphomas.
Cotta CV; Leventaki V; Atsaves V; Vidaki A; Schlette E; Jones D; Medeiros LJ; Rassidakis GZ
Cancer; 2008 Feb; 112(3):552-61. PubMed ID: 18085637
[TBL] [Abstract][Full Text] [Related]
33. Leptin-induced growth of human ZR-75-1 breast cancer cells is associated with up-regulation of cyclin D1 and c-Myc and down-regulation of tumor suppressor p53 and p21WAF1/CIP1.
Chen C; Chang YC; Liu CL; Chang KJ; Guo IC
Breast Cancer Res Treat; 2006 Jul; 98(2):121-32. PubMed ID: 16752079
[TBL] [Abstract][Full Text] [Related]
34. Down-regulation of c-Myc following MEK/ERK inhibition halts the expression of malignant phenotype in rhabdomyosarcoma and in non muscle-derived human tumors.
Marampon F; Ciccarelli C; Zani BM
Mol Cancer; 2006 Aug; 5():31. PubMed ID: 16899113
[TBL] [Abstract][Full Text] [Related]
35. Cooperation of Gata3, c-Myc and Notch in malignant transformation of double positive thymocytes.
van Hamburg JP; de Bruijn MJ; Dingjan GM; Beverloo HB; Diepstraten H; Ling KW; Hendriks RW
Mol Immunol; 2008 Jun; 45(11):3085-95. PubMed ID: 18471881
[TBL] [Abstract][Full Text] [Related]
36. c-Myc is essential for hematopoietic stem cell differentiation and regulates Lin(-)Sca-1(+)c-Kit(-) cell generation through p21.
Baena E; Ortiz M; Martínez-A C; de Alborán IM
Exp Hematol; 2007 Sep; 35(9):1333-43. PubMed ID: 17637497
[TBL] [Abstract][Full Text] [Related]
37. Defining the specific physiological requirements for c-Myc in T cell development.
Douglas NC; Jacobs H; Bothwell AL; Hayday AC
Nat Immunol; 2001 Apr; 2(4):307-15. PubMed ID: 11276201
[TBL] [Abstract][Full Text] [Related]
38. Genome-wide SNP analysis of Tg.AC transgenic mice reveals an oncogenic collaboration between v-Ha-ras and Ink4a, which is absent in p53 deficiency.
Leder A; McMenamin J; Zhou F; Moran JL; Beier DR; Leder P
Oncogene; 2008 Apr; 27(17):2456-65. PubMed ID: 17952114
[TBL] [Abstract][Full Text] [Related]
39. Detection of human papillomavirus and relevant tumor suppressors and oncoproteins in laryngeal tumors.
Manjarrez ME; Ocadiz R; Valle L; Pacheco C; Marroquin A; De la Torre C; Selman M; Gariglio P
Clin Cancer Res; 2006 Dec; 12(23):6946-51. PubMed ID: 17145812
[TBL] [Abstract][Full Text] [Related]
40. T-cell lymphomas mask slower developing B-lymphoid and myeloid tumours in transgenic mice with broad haemopoietic expression of MYC.
Smith DP; Bath ML; Harris AW; Cory S
Oncogene; 2005 May; 24(22):3544-53. PubMed ID: 15688022
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
